Company news
Apellis Pharmaceuticals, Inc. news in 2020
Apellis Pharmaceuticals, Inc.'s news releases, calls and decks from 2020, newest first.
Apellis Reports Pegcetacoplan Demonstrates Greater Treatment Responses and Quality-of-Life Improvements Compared to C5 Inhibitors for PNH
December 6, 2020
Apellis and Sobi Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan
November 18, 2020
Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of PNH
November 15, 2020
Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 Virtual
November 12, 2020
Apellis Pharmaceuticals Reports Third Quarter 2020 Financial Results
November 1, 2020
Apellis and Sobi Enter Collaboration for Global Co-development and Ex-US Commercialization of Systemic Pegcetacoplan in Rare Diseases with Urgent Need for New Treatments
October 26, 2020
Apellis Announces 18-Month Data from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy (GA)
October 18, 2020
Apellis Announces New Data Demonstrating Correlation between Complement Activation and COVID-19 Severity
October 14, 2020
Apellis Initiates Registrational Programs of Pegcetacoplan in Patients with C3G / IC-MPGN and ALS, Rare Diseases with High Unmet Need
October 4, 2020
Apellis Announces New Analysis Demonstrating Targeted C3 Therapy Pegcetacoplan Slows Progression of Early Disease in Patients with Geographic Atrophy (GA)
October 2, 2020
Apellis Announces Late-Breaking Presentation of Targeted C3 Therapy Pegcetacoplan in Patients with Geographic Atrophy (GA) at EURETINA 2020
September 20, 2020
Apellis Announces Submission of Pegcetacoplan Marketing Applications to FDA and EMA for Patients with PNH
September 14, 2020
Apellis Pharmaceuticals Reports Second Quarter 2020 Financial Results
July 30, 2020
Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)
July 6, 2020
Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
July 1, 2020
New Pivotal Data Demonstrate Superiority of Apellis’ Pegcetacoplan to Eculizumab in Improving Hemoglobin Levels, Independent of Prior Transfusions, in PNH
June 11, 2020
Apellis Announces Investor Conference Call to Discuss Phase 3 PEGASUS Data to be Presented at the 25th Annual Congress of the European Hematology Association (EHA)
June 9, 2020
Apellis Initiates Phase 1/2 Study of APL-9 in Patients with Severe COVID-19
May 27, 2020
Apellis Announces Plans to Submit NDA for Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH)
May 20, 2020
Apellis Pharmaceuticals Announces Private Placement of Convertible Senior Notes
May 6, 2020
Apellis Pharmaceuticals Reports First Quarter 2020 Financial Results
April 28, 2020
Paul Fonteyne Joins Apellis Board of Directors
April 5, 2020
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
February 26, 2020
Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
January 6, 2020